Hypothesis

We propose that progressive loss of 5-hydroxymethylcytosine (5hmC) at enhancer regions of the exhaustion-associated transcription factors ZSCAN20 and JDP2 underlies the stable epigenetic program of terminal CD8+ T-cell exhaustion. This 5hmC erosion reflects declining TET enzyme activity caused by oxidative-stress-induced accumulation of the oncometabolite 2-hydroxyglutarate (2-HG), which competitively inhibits TET catalysis. Consequently, enhancer hypermethylation silences ZSCAN20/JDP2, locking cells into an exhausted state that cannot be rescued by checkpoint blockade alone. Conversely, pharmacological elevation of hydrogen sulfide (H2S) activates TET1/2 via NFYB, restoring 5hmC deposition, reopening chromatin, and reinstating ZSCAN20/JDP2 expression to revert exhaustion.

Testable Predictions

• Prediction 1: In exhausted CD8+ T cells (defined by PD-1+TIM-3+LAG-3+ phenotype) derived from chronic infection or tumor models, joint-cabernet single-cell profiling will show significantly reduced 5hmC levels at enhancers marked by H3K27ac near the ZSCAN20 and JDP2 loci compared with memory CD8+ T cells, while 5mC will be reciprocally increased.
• Prediction 2: Ex vivo treatment of exhausted CD8+ T cells with a physiological H2S donor (e.g., NaHS) will increase TET1/2 activity (measured by 5hmC gain at FOXP3 CNS2 as a positive control) and specifically restore 5hmC at ZSCAN20/JDP2 enhancers, leading to ↑ZSCAN20 and ↓JDP2 transcripts and restored cytotoxic granule production (IFN-γ, granzyme B).
• Prediction 3: Pharmacological inhibition of TETs with cell-permeable 2-HG will mimic the exhaustion epigenetic signature in naïve CD8+ T cells cultured under strong TCR stimulation, causing decreased 5hmC at the same enhancers and premature upregulation of exhaustion markers even in the absence of chronic antigen exposure.

Experimental Approach

1. Cell models: Use the OT-I transgenic system infected with chronic LCMV clone 13 or adoptive transfer of P14 CD8+ T cells into melanoma-bearing mice to generate exhausted CD8+ T cells; isolate memory cells from acute LCMV Armstrong infection.
2. Multi-omics: Apply the Joint-Cabernet protocol ([2]) to simultaneously capture 5hmC, 5mC, and transcriptome from the same nuclei of exhausted vs memory CD8+ T cells. Focus analysis on enhancer regions (ATAC-seq peaks) overlapping ZSCAN20 and JDP2 loci.
3. Pharmacologic modulation: Treat exhausted cultures with NaHS (100 µM) or 2-HG (500 µM) for 24 h, then repeat Joint-Cabernet profiling and flow-cytometric assessment of exhaustion markers and effector functions.
4. Controls: Include TET1/2 double-knockout CD8+ T cells (CRISPR) to confirm that H2S effects are TET-dependent, and use a catalytically dead TET mutant as negative control.

Falsifiability

If joint-cabernet data reveal no significant difference in 5hmC at ZSCAN20/JDP2 enhancers between exhausted and memory cells, or if H2S treatment fails to increase 5hmC and rescue effector function despite confirmed TET activation, the hypothesis would be falsified. Likewise, if 2-HG exposure does not induce an exhaustion-like epigenetic profile in naïve cells, the proposed link between metabolic inhibition of TETs and exhaustion would be refuted.

Broader Impact

Demonstrating a direct, reversible epigenetic switch linking TET activity, 5hmC landscape, and exhaustion-specific transcription factors would provide a mechanistic bridge between oxidative stress, metabolic dysregulation, and immune senescence in aging and cancer. It would also justify exploring H2S-based epigenetic adjuvants to reinvigorate exhausted T cells in immunotherapy regimens.

References (inline)

• TET regulation of Treg and iNKT fate: 1
• Joint-Cabernet multi-omics method: 2
• Age-associated 5hmC accumulation in gene bodies: 3
• In vitro models of terminal CD8 exhaustion: 4
• ZSCAN20/JDP2 as exhaustion switches: 5